Oncogene

OCT 31, 2026 · JOURNAL ARTICLE

Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer

Oncogene

Abstract Hyperactivation of the mechanistic target of rapamycin (mTOR) complexes, mTORC1 and mTORC2, is common in pancreatic ductal adenocarcinoma (PDAC). However, clinical use of

OCT 17, 2026 · JOURNAL ARTICLE

Liver-specific amino acid metabolism impacts on efficacy of cancer immunotherapy

Oncogene

Abstract The combination immunotherapies, including those with atezolizumab and bevacizumab (Atez/Bev), have become standard therapy for hepatocellular carcinoma (HCC). However, it

SEP 12, 2026 · JOURNAL ARTICLE

Development and preclinical evaluation of a decoy DLL4-encoding oncolytic HSV-1 for high-grade glioma

Oncogene

Preclinical and clinical investigation of oncolytic HSV-1 (oHSV) treatment for cancer has indicated increased Notch signaling in tumors after treatment. Since Notch activation ofte

AUG 12, 2026 · JOURNAL ARTICLE

Clinical metastatic cancer from initiation to colonization: emerging challenges and breakthroughs

Oncogene

This is a narrative review synthesizing current knowledge on metastatic cancer biology; it raises questions and synthesizes existing evidence rather than presenting new empirical findings or a definitive answer.